FDA Announces Nivolumab Dose Change for RCC, NSCLC, Metastatic Melanoma

Article

The FDA announced a modification to the recommended dosage regimen for nivolumab (Opdivo) for renal cell carcinoma (RCC), metastatic melanoma, and non–small-cell lung cancer (NSCLC).

The US Food and Drug Administration (FDA) announced a modification to the recommended dosage regimen for nivolumab (Opdivo) for renal cell carcinoma (RCC), metastatic melanoma, and non–small-cell lung cancer (NSCLC). Nivolumab was originally approved at a single dose of 3 mg/kg intravenously (IV) every 2 weeks. For all three diseases, the new dosage is 240 mg IV every 2 weeks until disease progression or intolerable toxicity.

According to the FDA announcement, the approval of the dosage modification was based on population pharmacokinetics analyses and dose/exposure-response analyses that demonstrated the comparability of the pharmacokinetics exposure, safety, and efficacy of the proposed new dosing regimen with the 3 mg/kg every 2 weeks regimen.

Using simulations in the population pharmacokinetics model, the FDA determined that exposure to nivolumab at a dose of 240 mg every 2 weeks was similar to the 3 mg/kg every 2 weeks dose-less than a 6% difference in exposure. The differences in exposure are not likely to have a clinically meaningful effect on safety and efficacy, since dose/exposure response relationships appear to be relatively flat in these three indications.

The FDA announcement noted that the dose of nivolumab used in combination with ipilimumab for melanoma will not be changing. That dose will remain at 1 mg/kg IV followed by ipilimumab on the same day every 3 weeks for four doses. However, once the ipilimumab treatment is completed, the recommended nivolumab dose will be the new dosage of 240 mg every 2 weeks until disease progression or intolerable toxicity.

Finally, the recommended dose for classical Hodgkin lymphoma will remain 3 mg/kg IV every 2 weeks until disease progression or intolerable toxicity.

Recent Videos
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Experts weigh in on tumor-informed testing, false positives, relevant trial data, and other key concepts related to circulating tumor DNA.
Ongoing studies in kidney cancer aim to explore determinants of immune-related adverse effects and strategies for mitigating them.
Machine learning-based approaches may play a role in further understanding of how somatic alterations influence responses or resistance to therapy.
Data from a first-in-disease trial assessing a personalized cancer vaccine in RCC require validation at a larger level, according to David Braun, MD, PhD.
Experts highlight methods for optimally treating patients with genitourinary cancers harboring variant histologies at World GU 2025.
Blood-based markers of note in kidney cancer prognosis include circulating tumor DNA and proteomic markers, according to Michael B. Atkins, MD.
Clinical trials still have a role in improving outcomes with immunotherapy among those with kidney cancer.
Related Content